Modulation of Postoperative Scarring with Tacrolimus and Octreotide in Experimental Glaucoma Filtration Surgery

REFERENCES

• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–267.
   PubMed Web of Science ®Google Scholar
• McKinnon SJ, Goldberg LD, Peeples P, Walt JG, Bramley TJ. Current management of glaucoma and the need for complete therapy. Am J Manag Care. 2008;14:S20–S27.
   PubMedGoogle Scholar
• Sharaawy T, Bhartiya S. Surgical management of glaucoma: evolving paradigms. Indian J Ophthalmol. 2011;59 Suppl:S123–S130.
   PubMedGoogle Scholar
• Dietlein TS, Hermann MM, Jordan JF. The medical and surgical treatment of glaucoma. Dtsch Arztebl Int. 2009;106:597–605; quiz 606.
   PubMedGoogle Scholar
• Razeghinejad MR, Spaeth GL. A history of the surgical management of glaucoma. Optom Vis Sci. 2011;88:E39–E47.
   PubMed Web of Science ®Google Scholar
• Mendrinos E, Mermoud A, Shaarawy T. Nonpenetrating glaucoma surgery. Surv Ophthalmol. 2008;53:592–630.
   PubMed Web of Science ®Google Scholar
• Coppens G, Maudgal P. Corneal complications of intraoperative Mitomycin C in glaucoma surgery. Bull Soc Belge Ophtalmol. 2010;314:19–23.
   Google Scholar
• Jongsareejit B, Tomidokoro A, Mimura T, Tomita G, Shirato S, Araie M. Efficacy and complications after trabeculectomy with mitomycin C in normal-tension glaucoma. Jpn J Ophthalmol. 2005;49:223–227.
   PubMedGoogle Scholar
• Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet. 2007;22:328–335.
   PubMed Web of Science ®Google Scholar
• Fort J, Oberti F, Pilette C et al. Antifibrotic and hemodynamic effects of the early and chronic administration of octreotide in two models of liver fibrosis in rats. Hepatology. 1998;28:1525–1531.
   PubMedGoogle Scholar
• Xiao YQ, Liu K, Shen JF, Xu GT, Ye W. SB-431542 inhibition of scar formation after filtration surgery and its potential mechanism. Invest Ophthalmol Vis Sci. 2009;50:1698–1706.
   PubMed Web of Science ®Google Scholar
• Vijaya L, Manish P, Ronnie G, Shantha B. Management of complications in glaucoma surgery. Indian J Ophthalmol. 2011;59 Suppl:S131–S140.
   PubMedGoogle Scholar
• Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol. 2003;48:314–346.
   PubMed Web of Science ®Google Scholar
• Filippopoulos T, Hanna E, Chen TC, Grosskreutz CL, Jakobiec FA, Pasquale LR. Correlation of filtration bleb morphology with histology. Int Ophthalmol Clin. 2009;49:71–82.
   PubMedGoogle Scholar
• Wang XY, Crowston JG, Zoellner H, Healey PR. Interferon-alpha and interferon-gamma sensitize human tenon fibroblasts to mitomycin-C. Invest Ophthalmol Vis Sci. 2007;48:3655–3661.
   PubMed Web of Science ®Google Scholar
• Carvalho CS, Viveiros MM, Schellini SA, Candeias JM, Padovani CR. [Fibroblasts from recurrent pterygium and normal Tenon’s capsule exposed to tacrolimus (FK-506)]. Arq Bras Oftalmol. 2007;70:235–238.
   PubMedGoogle Scholar
• Hofland LJ, van der Burg B, van Eijck CH, Sprij DM, van Koetsveld PM, Lamberts SW. Role of tumor-derived fibroblasts in the growth of primary cultures of human breast-cancer cells: effects of epidermal growth factor and the somatostatin analogue octreotide. Int J Cancer. 1995;60:93–99.
   PubMedGoogle Scholar
• Chang L, Crowston JG, Cordeiro MF, Akbar AN, Khaw PT. The role of the immune system in conjunctival wound healing after glaucoma surgery. Surv Ophthalmol. 2000;45:49–68.
   PubMed Web of Science ®Google Scholar
• Futamura Y, Matsumoto K. Characteristics of peripheral blood monocytes and bone marrow macrophages from rats treated with mitomycin C, 5-fluorouracil or phenylhydrazine. J Toxicol Sci. 1995;20:1–7.
   PubMedGoogle Scholar
• Lattuada D, Casnici C, Crotta K et al. Inhibitory effect of pasireotide and octreotide on lymphocyte activation. J Neuroimmunol. 2007;182:153–159.
   PubMedGoogle Scholar
• Wiedermann CJ, Reinisch N, Braunsteiner H. Stimulation of monocyte chemotaxis by human growth hormone and its deactivation by somatostatin. Blood. 1993;82:954–960.
   PubMed Web of Science ®Google Scholar
• Horigome A, Hirano T, Oka K. Tacrolimus-induced apoptosis and its prevention by interleukins in mitogen-activated human peripheral-blood mononuclear cells. Immunopharmacology. 1998;39:21–30.
   PubMed Web of Science ®Google Scholar
• Cordeiro MF, Reichel MB, Gay JA, D’Esposita F, Alexander RA, Khaw PT. Transforming growth factor-beta1, -beta2, and -beta3 in vivo: effects on normal and mitomycin C-modulated conjunctival scarring. Invest Ophthalmol Vis Sci. 1999;40:1975–1982.
   PubMed Web of Science ®Google Scholar
• Giordano A, Romano S, Mallardo M et al. FK506 can activate transforming growth factor-beta signalling in vascular smooth muscle cells and promote proliferation. Cardiovasc Res. 2008;79:519–526.
   PubMedGoogle Scholar
• Hasegawa T, Sumiyoshi K, Tsuchihashi H, Ikeda S, Nakao A, Ogawa H. FK506 inhibits the enhancing effects of TGF-beta on wound healing in a rabbit dermal ulcer model. J Dermatol Sci. 2007;47:37–40.
   PubMedGoogle Scholar
• Erol FS, Kavakli A, Ilhan N, Ozercan IH, Sarsilmaz M. Efects of melatonin and octreotide on peridural fibrosis in an animal model of laminectomy. Turk Neurosurg. 2010;20:50–56.
   PubMedGoogle Scholar
• Occleston NL, Daniels JT, Tarnuzzer RW et al. Single exposures to antiproliferatives: long-term effects on ocular fibroblast wound-healing behavior. Invest Ophthalmol Vis Sci. 1997;38:1998–2007.
   PubMed Web of Science ®Google Scholar
• Fealy MJ, Most D, Huie P et al. Association of down-regulation of cytokine activity with rat hind limb allograft survival. Transplantation. 1995;59:1475–1480.
   PubMedGoogle Scholar
• Erten C, Karaca B, Kucukzeybek Y et al. Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide. BJU Int. 2009;104:107–114.
   PubMedGoogle Scholar
• Dumont FJ. FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem. 2000;7:731–748.
   PubMed Web of Science ®Google Scholar
• Yang LP, Keating GM. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs. 2010;70:1745–1769.
   PubMed Web of Science ®Google Scholar
• Sener G, Cetinel S, Erkanli G, Gedik N, Yegen BC. Octreotide ameliorates sepsis-induced pelvic inflammation in female rats by a neutrophil-dependent mechanism. Peptides. 2005;26:493–499.
   PubMed Web of Science ®Google Scholar
• Ohashi Y, Ebihara N, Fujishima H et al. A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther. 2010;26:165–174.
   PubMed Web of Science ®Google Scholar
• Akyol N, Demir T, Cobanoglu B, Ulas F. Ciliary body toxicity of cyclosporin A and octreotide acetate in rabbit eyes: a comparison with mitomycin C and 5-fluorouracil. Graefes Arch Clin Exp Ophthalmol. 2003;241:816–822.
   PubMedGoogle Scholar
• Demir T, Turgut B, Celiker U, Ozercan I, Ulas F, Akyol N. Effects of octreotide acetate and amniotic membrane on wound healing in experimental glaucoma surgery. Doc Ophthalmol. 2003;107:87–92.
   PubMed Web of Science ®Google Scholar
• Hikita N, Lopez JS, Chan CC, Mochizuki M, Nussenblatt RB, de Smet MD. Use of topical FK506 in a corneal graft rejection model in Lewis rats. Invest Ophthalmol Vis Sci. 1997;38:901–909.
   PubMed Web of Science ®Google Scholar